Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines
(1993; 94 pages)
Índice de contenido
Ver el documentoFOREWORD
Abrir esta carpeta y ver su contenido1. INTRODUCTION
Abrir esta carpeta y ver su contenido2. GENERAL CONSIDERATIONS IN HERBAL MEDICINE RESEARCH
Cerrar esta carpeta3. RESEARCH STUDIES
Ver el documentoLITERATURE BACKGROUND
Ver el documentoPROTOCOL PREPARATION
Ver el documentoQUALITY SPECIFICATIONS OF PLANT MATERIALS AND PREPARATION
Abrir esta carpeta y ver su contenidoNON-CLINICAL STUDIES
Cerrar esta carpetaCLINICAL TRIALS USING HERBAL MEDICINES
Ver el documentoCLINICAL TRIAL PROTOCOL DEVELOPMENT
Ver el documentoPHASES OF A CLINICAL TRIAL
Ver el documentoETHICS REVIEW BOARD
Ver el documentoRESPONSIBILITIES OF INVESTIGATORS
Ver el documentoRESPONSIBILITIES OF THE SPONSOR
Ver el documentoDATA MANAGEMENT
Ver el documentoSTATISTICAL ANALYSIS
Ver el documentoREPORTING
Ver el documentoEVALUATION OF HERBAL MEDICINE RESEARCH
Abrir esta carpeta y ver su contenidoTECHNOLOGY TRANSFER AND EDUCATION
Abrir esta carpeta y ver su contenido4. USING THE GUIDELINES
Abrir esta carpeta y ver su contenidoANNEXES
Ver el documentoNOTES
Ver el documentoBIBLIOGRAPHY
Ver el documentoSELECTED WHO PUBLICATIONS OF RELATED INTEREST
 

ETHICS REVIEW BOARD

The trial protocol should be considered by an ethics review board. The board will generally be established at an institutional level but boards existing at a regional or national level can also be used. The board will be an independent body constituted of both medical and non-medical members who are not involved in the experimental activity of the trial under review. The board will verify that the rights of the patients participating in the trial are protected and that the trial is justified in medical and social terms. The board will also consider the suitability of the trial protocol, patient selection and patient protection, and issues of informed consent of patients. The work of the board should be guided by the World Medical Association’s Declaration of Helsinki (Annex 2).

The board will work under standard operating procedures which will be developed by each institution taking into consideration all necessary requirements of local regulatory authorities and related governmental agencies including such rules as those for Good Clinical Practice (GCP).

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013